RT @OFIDJournal: Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomi…
735 followers
16,055 followers
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial 🔓 Open Access https://t.co/0cOY5Brypk
606 followers
** UPDATED ** the strong recommendation against the use of sotrovimab in patients with non-severe COVID-19 (first published 14 January 2022, updated 16 Sept 2022, updated 13 January 2023) with new evidence of the reduction of effectiveness of sotrovimab a…
16,055 followers
Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial ✅ Just Accepted 🔓 Open Access 🔗 https://t.co/3woDDJLdTU https://t.co/1Ff2NO4uug